FOXO4-DRI

🔹 What is FOXO4-DRI?

Class: Synthetic peptide—designed peptide inhibitor targeting the FOXO4-p53 interaction. Mechanism: Selectively induces apoptosis in senescent cells by disrupting the interaction between FOXO4 and p53. This removes cells that contribute to aging, chronic inflammation, and tissue dysfunction, potentially improving regenerative capacity and reducing senescence-related pathologies. Primary focus: Senescent cell clearance, longevity, tissue regeneration, reduced chronic inflammation, and potential anti-aging effects.

---

🔹 Oral Dosage (least common) Range studied/used in research: Oral bioavailability is negligible; peptide is degraded in the GI tract. Typical protocol: Not used orally; all effective applications are via subcutaneous or intravenous injection. Notes: Oral administration is impractical; systemic delivery is necessary for senolytic activity.

---

🔹 Injectable / Subcutaneous / Intravenous Dosage (most common) Range: Research in animal models typically uses 5–10 mg/kg per dose, administered intermittently. Human anecdotal protocols are much lower, often in the microgram per kg range, but clinical human dosing is not well-established. Frequency: Intermittent dosing is used (e.g., weekly or monthly), as senescent cell clearance does not require daily administration. Rationale: Pulsed administration avoids excessive cell death in non-senescent tissues while targeting senescent cells selectively.

---

🔹 Cycle Length Common cycle length: Short-term cycles of 1–4 weeks are typical in research settings, often repeated after several months depending on goals. Off-cycle: Extended breaks of weeks to months are used to monitor effects and tissue response. Note: Duration and repetition are extrapolated from animal studies; formal human clinical data is limited.

---

🔹 Optimal Dosing Window Injectable / Subcutaneous / IV: Timing is flexible; intermittent dosing during active hours is common in research models. Daytime dosing may support better tissue recovery cycles, but specific human timing data is limited.

---

✅ Educational Integration Example (injectable / subcutaneous) Example protocol: 50 µg subcutaneous injection three times per week for 2 weeks, followed by a 4-week break. Pair with: Supportive recovery strategies—adequate sleep, antioxidants, NAD⁺ precursors, and tissue-supportive nutrients.

---

🔹 Stacking Strategy (Educational) Since FOXO4-DRI targets senescent cells and longevity pathways, stacks focus on regenerative, anti-aging, and metabolic support: 🔸 Senescence & Longevity Support

• Epitalon: Telomere maintenance and cellular health support.
• NAD⁺ precursors (NMN/NR): Enhance mitochondrial function and repair post-senolytic cycles.

🔸 Tissue Recovery & Regeneration

• BPC-157 or TB-500: Supports tissue repair following senescent cell clearance.
• Collagen, antioxidants: Aid systemic tissue integrity and recovery.

🔸 Metabolic & Hormonal Support

• CJC-1295 or GH secretagogues: Promote regenerative and anabolic pathways.
• AOD-9604: Supports fat metabolism and energy during recovery periods.

Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.